Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Therapeutic
- Arthritis
- Disease
- Drug Discovery
- Antibody
- Pharmaceuticals
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 231728
License Grant
The Licensor granted the Bermudan Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. a human monoclonal antibody for the treatment of rheumatoid arthritis.
License Property
The Licensor also granted reference rights to relevant manufacturing and regulatory documents and existing supply of mavrilimumab drug substance and product.
Field of Use
The Bermudan Licensee is obligated to use commercially reasonable efforts to develop and commercialize the licensed products. The investigational drug may be used as a rheumatoid arthritis treatment.
IPSCIO Record ID: 26092
License Grant
The Compny announced that it had reached a settlement agreement.
License Property
Humira(R) is licensed to Licensee, is the first Licensor-derived antibody to be approved for marketing. It was isolated and optimized in collaboration with Licensee and has been approved for marketing as a treatment for rheumatoid arthritis (RA) in 57 countries, and for Psoriatic arthritis and early RA in some European countries and the US.
Humira (adalimumab) is a fully human anti-TNFa monoclonal antibody, isolated and optimized by Licensor in collaboration with Licensee and now approved for marketing as a treatment for rheumatoid arthritis or RA, early RA and Psoriatic arthritis. Humira (adalimumab) is Licensor's only marketed product, approved as a rheumatoid arthritis treatment.
IPSCIO Record ID: 289246
License Grant
Licensor grants the Chinese Licensee an exclusive, non-transferable, perpetual license in the field of Therapeutic usage in order to develop and conduct clinical trials to achieve Chinese FDA (SFDA) approval of the rabbit anti-TNFalpha monoclonal antibody compounds. Under these rights, Licensor grants both the manufacturing and distribution rights of anti-TNFalpha monoclonal antibody therapeutics covered under the intellectual properties rights owned by Licensor.
License Property
Licensor utilizes a proprietary and patented technology in the development and production of Rabbit Monoclonal Antibodies (RabMAb technology).
Licensor has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies that are highly potent compared with Remicade and Humira in in-vitro assays.
Licensor will provide Humanized Rabbit anti-TNFalpha monoclonal antibodies to Licensee.
Field of Use
The field is for commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents. Anti-TNFalpha therapies are effective in treating Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Ankylosing spondylis and Crohns diseases.
IPSCIO Record ID: 245716
License Grant
The Swiss Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, for Licensee and its Affiliates to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
The nti-IL6R antibodies marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. The Licensee intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases.
Field of Use
Field means any and all uses including all therapeutic uses. Licensed IP includes the nti-IL6R antibodies for a range of inflammatory conditions including rheumatoid arthritis.
Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (“BMSâ€), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.
IPSCIO Record ID: 311941
License Grant
Licensor granted Bermuda Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. Under the original Agreement, the Licensee also acquired reference rights to relevant manufacturing and regulatory documents and Licensor’s existing supply of mavrilimumab drug substance and product. This amendment allows the Licensee to establish a new coronavirus field and defer the payment of certain development and regulatory milestones as applied to the new coronavirus field.
License Property
Mavrilimumab is a monoclonal antibody that antagonizes granulocyte-macrophage colony stimulating factor, or GM-CSF.
Licensor is a biopharmaceutical company known for its vaccine technology and offers biological products, therapeutic and preventive medicines.
Field of Use
The field of use is in the treatment of coronavirus 2019, or COVID-19, a pneumonia and hyperinflammation disease and giant cell arteritis, or GCA, a chronic inflammatory disease of the medium-to-large arteries.
Licensee is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need. Licensee has a pipeline of clinical-stage product candidates that are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways that are implicated across a spectrum of diseases.
IPSCIO Record ID: 240459
License Grant
The Taiwan Licensor granted the Taiwan Licensee non-exclusive licensing rights to use, modify and manufacture BEL-DLS03, an API designed to treat rheumatoid arthritis, and its analysis platform for therapeutic and dietary purposes. In accordance with the Licensor BLI-1007 License Agreement and its Amendment, in 2016 the License became an exclusive licensing right to use patent of BEL-DLS03 and the manufacturing method.
License Property
BEL-DLS03 Patent, an API designed to treat rheumatoid arthritis, and its analysis platform for therapeutic and dietary purposes.
Field of Use
The Licensee was conducting preclinical studies of BEL-DLS03, which is the API for drug candidate BLI-1007 for Rheumatoid Arthritis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
